Cargando…

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics

Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung cancer. Irinotecan therapy is characterized by several dose-limiting toxicities and large interindividual pharmacokineti...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Man, Femke M., Goey, Andrew K. L., van Schaik, Ron H. N., Mathijssen, Ron H. J., Bins, Sander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132501/ https://www.ncbi.nlm.nih.gov/pubmed/29520731 http://dx.doi.org/10.1007/s40262-018-0644-7

Ejemplares similares

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
por: de With, Mirjam, et al.
Publicado: (2023)

The Impact of Pharmacogenetics on Pharmacokinetics and Pharmacodynamics in Neonates and Infants: A Systematic Review
por: Yalçin, Nadir, et al.
Publicado: (2022)

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
por: Mathijssen, R H J, et al.
Publicado: (2002)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020)

Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics
por: Brunet, Mercè, et al.
Publicado: (2022)

Individualization of Mycophenolic Acid Therapy through Pharmacogenetic, Pharmacokinetic and Pharmacodynamic Testing
por: Winnicki, Wolfgang, et al.
Publicado: (2022)

Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
por: Teng, Renli
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
por: Yu, Meng, et al.
Publicado: (2018)

6. Dose Adjustments Based on Pharmacogenetics of CYP450 Enzymes
por: van Schaik, Ron H.N.
Publicado: (2008)

Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy
por: Alvitigala, Bhawani Yasassri, et al.
Publicado: (2020)

Clinical Application of Pharmacogenetics: Where are We Now?
por: van Schaik, Ron HN
Publicado: (2014)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

Pharmacogenetics in Psychiatry: An Update on Clinical Usability
por: van Schaik, Ron H. N., et al.
Publicado: (2020)

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
por: Bins, Sander, et al.
Publicado: (2018)

Call for Manuscript Submissions for a Thematic eJIFCC Issue on “Pharmacogenetics and Personalized Therapy”
por: van Schaik, Ron H. N., et al.
Publicado: (2022)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

Proton Pump Inhibitors in Pediatrics: Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics
por: Ward, Robert M., et al.
Publicado: (2013)

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
por: Allegrini, G, et al.
Publicado: (2008)

Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients
por: Ahmed, Jemal Hussien, et al.
Publicado: (2020)

CYP3A4(∗)22 Genotyping in Clinical Practice: Ready for Implementation?
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure
por: Bins, Sander, et al.
Publicado: (2016)

Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children
por: Verscheijden, Laurens F. M., et al.
Publicado: (2021)

Effects of methimazole on the elimination of irinotecan
por: van der Bol, Jessica M., et al.
Publicado: (2010)

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
por: Berends, Sophie E., et al.
Publicado: (2018)

A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients
por: Oosten, Astrid W., et al.
Publicado: (2016)

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer
por: Diekstra, MH, et al.
Publicado: (2017)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
por: Wu, Huali, et al.
Publicado: (2015)

Implementation of Pharmacogenetics in First-Line Care: Evaluation of Its Use by General Practitioners
por: van der Drift, Denise, et al.
Publicado: (2023)

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
por: Anthoney, D Alan, et al.
Publicado: (2012)

Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients
por: Agema, Bram C., et al.
Publicado: (2020)

Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer
por: van Eerden, Ruben A. G., et al.
Publicado: (2021)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Publicado: (2019)

Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing
por: Yin, Anyue, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
por: Appeldoorn, T. Y. J., et al.
Publicado: (2023)

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
por: de With, Mirjam, et al.
Publicado: (2021)

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK(2)-PD) relationship of tacrolimus in liver transplant recipients
por: Tron, Camille, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis
por: Zhang, Cindy X., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_92igc5nne6j03dacnp07s3cuud